Connect with us

CBD News

Sundial Growers Nasdaq IPO: Here’s What to Know About the $130 Million Plan



Sundial Growers Nasdaq IPO: Here's What to Know About the $130 Million Plan

Alberta-based CBD company Sundial Growers announced in a press release that it has launched an initial public offering (“IPO”) of its common shares in Canada and in the United States. The IPO was launched pursuant to a statement on Form F-1 filed with the United States Securities Exchange Commission. The ticker symbol is SDNL.

The company is offering 10,000,000 common shares at an initial price to the public. The value of the estimated shares is around $12.00 to $14.00 USD per share. A prospectus will be the means by which the offering will be made.

Andrew is a full-time professional writer in Canada with over 8 years of esteemed experience. He is one of the best cannabis health researchers, polished legal investigators and active CBD news reporters we have at TOC. While being featured in hundreds of health, technology, science, and even bitcoin publications; Andrew's now on the frontline of the Canadian cannabis culture and will continue breaking down everything so easily your grandma can understand hemp and CBD.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.